Selling a Medical Technology Company – Maximize Price, Reduce Risks & Protect Employees
What should I pay attention to when selling my medical technology company? What is important for a high company valuation? And how do I protect my employees during the sale?
You notice it fairly quickly. Once you start engaging with the topic of selling a company, there is no stopping. Questions and thoughts come flooding in. Be it general questions like: What is EBITDA and how do I calculate it for my company, or why do I need EBITDA? down to: Do I have to sell my car when selling my company?
All important questions — but let us rewind to the beginning. At the start of a sales process:
Ask yourself the following questions before taking the first step toward selling your company:
- Why do I want to sell (age-related, illness, no longer interested in the business, growth capital)?
- What are my top three requirements that must be met in a company sale?
- Do I want to fully withdraw or take on an advisory or strategic role — am I ready to give up control, even if decisions are made differently in the future than I would make them?
- How do I envision my daily life after the sale — professionally and privately?
After asking yourself these questions, we come to the actual
Main question: I want to sell my medical technology company — but how?
Selling MedTech — how do I approach it?
Selling a medical technology company is not an ordinary M&A process. Here it is not enough to simply put some numbers and a glossy presentation on the table. In MedTech, regulation determines the price — and that is precisely the biggest hurdle for many sellers. Certificates, MDR transition periods, EUDAMED, PRRC, supply chains, international customer relationships, and the high liability risks of defective products: Whoever is not perfectly prepared here will quickly find an experienced buyer using exactly these points as price leverage.
Therefore one thing is clear: You need clean documentation. A traceable business plan, clear regulatory roadmaps, and a prepared data room are mandatory if you want to achieve a fair and high price.
Starting position — before approaching buyers
Before contacting the first interested party, clarify your own starting position. What is your target picture and what time horizon is realistic? In MedTech, a sales process typically takes 9 to 18 months. Do you want a share deal where the manufacturer identity remains, or an asset deal that may have tax advantages but is significantly more risky from a regulatory perspective? What role do you want to take after closing — fully out or staying on as an advisor? And what are absolute no-gos you will not negotiate on — location, brand, employment?
Regulation as a price lever
In no other area is regulation so directly linked to the purchase price as in MedTech. Buyers pay for predictability. Anyone who can demonstrate that certificates are valid, MDR transition periods are met, EUDAMED data is properly maintained, and a PRRC is appointed takes the risk away from buyers. The result: fewer renegotiations and a higher multiple. Conversely, unclear documentation and open questions almost automatically lead to deductions.
What really drives the purchase price of a MedTech company?
Beyond regulation, it is always the same factors: recurring revenues (disposables, service contracts, software subscriptions), clean EBITDA figures without one-time effects, secured reimbursement systems, stable supply chains, IP protection, and a functioning management team. A buyer does not just look at what exists today, but at the question: How predictable and low-risk are the next five years?
Not every MedTech is the same
An implant manufacturer is valued based on clinical evidence and traceability, an IVD company based on performance evaluation and margins, a software company based on effectiveness and subscription revenues. For OEMs and contract manufacturers, validated specialized processes count; for distributors, exclusive contracts and tender success. As a seller, you must tailor your equity story precisely to your type.
Deal structure, employees, and roadmap
The deal structure is also crucial. A share deal is usually the lower-risk path; asset deals often harbor nasty surprises. Earn-outs can bridge gaps but should be measurable and clearly defined. At the same time, you must not forget your team: Section 613a BGB protects employment relationships, but only if the information is provided correctly. Mistakes here risk lawsuits — and buyers immediately see risks. Retention bonuses, phantom shares, or clear communication help stabilize the team during the process.
A professionally prepared data room with financial metrics, regulatory documents, IP evidence, and organizational charts is the key to smooth due diligence. Having everything ready signals: We are professional and deal-ready.
Typical deal killers
And finally: the typical pitfalls. Unclear certificate status, old vigilance issues, high customer concentration, single points of failure in the supply chain, no appointed PRRC, unmaintained EUDAMED data, asset deal traps, weak financials, an overly aggressive M&A law firm team, or faulty employee notifications. All of these are points that can be properly prepared — if you know about them. Closing these gaps in advance prevents nasty surprises, shortens the process, and ultimately achieves a significantly better price.
Disclaimer
This article was prepared with the greatest care and to the best of our knowledge. Nevertheless, no guarantee can be given for the accuracy, completeness, or timeliness of the content. The information is for general informational purposes only and does not constitute legal, tax, or business strategic advice. Individual review by qualified professionals is expressly recommended. The author and Adams Strategy assume no liability for any decisions or actions taken based on this article.
Do you need support with your sales process? Feel free to contact us: valuation@adamsstrategy.de
Note: This article is part of our healthcare industry series. Contact us at valuation@adamsstrategy.de for M&A advisory in the healthcare sector.